The lowest priced copy Van Cleef and Arpelscuff bracelet Really don't forget from zroessgs viesoess's blog
argenx NV ARGX
Mr. Tim Van Hauwermeiren is Chief Executive Officer of arGEN X BV. Tim has 18 years of business development and operational management experience within the biotech and consumer goods sectors. During which time he has played a key role in a number of fund raisings, IPO and the negotiation of a number of major licensing deals. Prior to becoming CEO of arGEN X, he was senior Business Development Manager at Ablynx NV where we was part of the team that negotiated a $265 million research development deal with Boehringer Ingelheim in 2007. Prior to joining Ablynx, Tim held various management positions with the Procter Gamble Company in R and Business Development,van cleef fleurette necklace replica, where he conceived and developed several new products. Among those was a healthcare innovation which won the United Nations ICC World Business Award in 2004. Tim holds a Master of Science degree in Bio engineering from the University of Gent (Belgium) and received general management training at INSEAD and The Vlerick School of Management (Executive MBA).
Mr. Mr. Castaldi has 27 years of international financial executive management experience, including 18 years in the biopharmaceutical industry. Before joining arGEN X,van cleef pendant necklace replica, Mr. Castaldi was CFO from 1998 to 2013 at Nicox, a Euronext listed biotech company. At Nicox, he was a member of the Executive committee and participated in all the financings of the company since its IPO in November 1999. From 2008 to 2012 he also served as board member and chairman of the audit committee of Hybrigenics, a French biopharmaceutical company specialized in oncology and listed on Euronext. Prior to this he was CFO at Safety Kleen Corporation, a US based environmental waste company,tiffany s necklace replica, where he was responsible for operations in France and Belgium. From 1989 through 1997, he was CFO in charge of French and German operations, at My Kinda Town plc, a European leisure company. During that period, he was involved in the 1994 flotation of that company on the London Stock Exchange. From 1986 through 1989, he was employed as Financial Analyst at the Research and Development Centre, located in Sophia Antipolis, of Cordis Corporation, a US based company specialized in bio surgical instrumentation. He graduated in Finance,van cleef arpel alhambra necklace replica, Accountancy and Administration from the University of Nice in 1986.
Ms. Debbie has been active in the antibody engineering field since the 1980s. She brings to arGEN X more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. She established her Business Development career at Cambridge Antibody Technology (now MedImmune), where she had management responsibility for technology, intellectual property and product out licensing, corporate equity, co development and cross license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the monoclonal antibody drug BENLYSTA (belimumab), now approved for the treatment of systemic lupus erythematosus. Prior to joining arGEN X, Debbie acted for eight years as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.
Dr. Michael Saunders is Senior Director, Targets Programs of arGEN X BV. He has twenty years of small molecule and biological drug discovery experience from both pharmaceutical and biotechnology, spanning several therapeutic areas. He has experience in target selection, project leadership, and project management. He holds a Doctoral degree from University of North Carolina in United States, a Bachelor of Arts in natural sciences from Cambridge University in United Kingdom, and an Executive Master's in Business Administration from ESSEC business school in Germany.
Dr. Alain Thibault serves as Chief Medical Officer of arGEN X BV. He has clinical development experience in oncology, both in the United States and Europe. Prior to joining arGEN X, he was therapeutic area head of Oncology at Regeneron Pharmaceuticals where he was responsible for clinical development, product strategy and portfolio management, as well as coordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications. He previously held senior research positions at Johnson Johnson and Hoffman La Roche before joining Regeneron. Dr. Thibault holds a Doctorate of Medicine from the McGill University (Canada).
Dr. John de Koning is Member of the Supervisory Board of arGEN X BV. Dr. de Koning is Partner at LSP (Life Sciences Partners), an independent European investment firm, providing financing to private and public life science companies. He serves or has served on the supervisory boards of arGEN X, BMEYE (acquired by Edwards Lifesciences), Innovative Biosensors Inc., Merus, Pronota, Prosensa, and Skyline Diagnostics. Dr. de Koning has a Master's degree in Molecular Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University of Rotterdam.
Dr. David L. Lacey is Member of the Supervisory Board of arGEN X BV. He moved from academia to an industry setting when he joined Amgen. During the last five years of his tenure he assumed the head of Discovery Research (> 1200 FTEs) for Amgen. In this capacity, he charted the course and motivated a diverse senior team of scientific leaders from different disciplines as well as engaging and managing a diverse stakeholder network. At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders, and neuroscience.
Dr. Bruno Montanari is Member of the Supervisory Board of arGEN X BV. He is a Director at Omnes Capital's Life Sciences Venture Capital team, which he joined in January 2010. He began his career in 1999 in London as an Investment Banker in the Healthcare Groups of Deutsche Bank and Merrill Lynch, later joining the venture capital community first with CDP Capital and then Atlas Venture, responsible for several European portfolio companies in the biotech and medtech areas as board member or observer.
Dr. Harrold van Berlingen is Member of the Supervisory Board of arGEN X BV. He is the Managing Director and Founder of Thuja Capital. He headed the life sciences effort of AlpInvest Partners managing a portfolio of over 30 companies, prior to founding Thuja Capital in 2006. Dr. van Barlingen joined AlpInvest Partners in 2001, from the Boston Consulting Group (BCG), where he worked as a consultant in management and strategy. Before BCG, he was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an internationally active firm specialized in the field of health economics.
Mr. Tim Van Hauwermeiren is Chief Executive Officer of arGEN X BV. Tim has 18 years of business development and operational management experience within the biotech and consumer goods sectors. During which time he has played a key role in a number of fund raisings, IPO and the negotiation of a number of major licensing deals. Prior to becoming CEO of arGEN X, he was senior Business Development Manager at Ablynx NV where we was part of the team that negotiated a $265 million research development deal with Boehringer Ingelheim in 2007. Prior to joining Ablynx, Tim held various management positions with the Procter Gamble Company in R and Business Development,van cleef fleurette necklace replica, where he conceived and developed several new products. Among those was a healthcare innovation which won the United Nations ICC World Business Award in 2004. Tim holds a Master of Science degree in Bio engineering from the University of Gent (Belgium) and received general management training at INSEAD and The Vlerick School of Management (Executive MBA).
Mr. Mr. Castaldi has 27 years of international financial executive management experience, including 18 years in the biopharmaceutical industry. Before joining arGEN X,van cleef pendant necklace replica, Mr. Castaldi was CFO from 1998 to 2013 at Nicox, a Euronext listed biotech company. At Nicox, he was a member of the Executive committee and participated in all the financings of the company since its IPO in November 1999. From 2008 to 2012 he also served as board member and chairman of the audit committee of Hybrigenics, a French biopharmaceutical company specialized in oncology and listed on Euronext. Prior to this he was CFO at Safety Kleen Corporation, a US based environmental waste company,tiffany s necklace replica, where he was responsible for operations in France and Belgium. From 1989 through 1997, he was CFO in charge of French and German operations, at My Kinda Town plc, a European leisure company. During that period, he was involved in the 1994 flotation of that company on the London Stock Exchange. From 1986 through 1989, he was employed as Financial Analyst at the Research and Development Centre, located in Sophia Antipolis, of Cordis Corporation, a US based company specialized in bio surgical instrumentation. He graduated in Finance,van cleef arpel alhambra necklace replica, Accountancy and Administration from the University of Nice in 1986.
Ms. Debbie has been active in the antibody engineering field since the 1980s. She brings to arGEN X more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. She established her Business Development career at Cambridge Antibody Technology (now MedImmune), where she had management responsibility for technology, intellectual property and product out licensing, corporate equity, co development and cross license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the monoclonal antibody drug BENLYSTA (belimumab), now approved for the treatment of systemic lupus erythematosus. Prior to joining arGEN X, Debbie acted for eight years as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.
Dr. Michael Saunders is Senior Director, Targets Programs of arGEN X BV. He has twenty years of small molecule and biological drug discovery experience from both pharmaceutical and biotechnology, spanning several therapeutic areas. He has experience in target selection, project leadership, and project management. He holds a Doctoral degree from University of North Carolina in United States, a Bachelor of Arts in natural sciences from Cambridge University in United Kingdom, and an Executive Master's in Business Administration from ESSEC business school in Germany.
Dr. Alain Thibault serves as Chief Medical Officer of arGEN X BV. He has clinical development experience in oncology, both in the United States and Europe. Prior to joining arGEN X, he was therapeutic area head of Oncology at Regeneron Pharmaceuticals where he was responsible for clinical development, product strategy and portfolio management, as well as coordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications. He previously held senior research positions at Johnson Johnson and Hoffman La Roche before joining Regeneron. Dr. Thibault holds a Doctorate of Medicine from the McGill University (Canada).
Dr. John de Koning is Member of the Supervisory Board of arGEN X BV. Dr. de Koning is Partner at LSP (Life Sciences Partners), an independent European investment firm, providing financing to private and public life science companies. He serves or has served on the supervisory boards of arGEN X, BMEYE (acquired by Edwards Lifesciences), Innovative Biosensors Inc., Merus, Pronota, Prosensa, and Skyline Diagnostics. Dr. de Koning has a Master's degree in Molecular Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University of Rotterdam.
Dr. David L. Lacey is Member of the Supervisory Board of arGEN X BV. He moved from academia to an industry setting when he joined Amgen. During the last five years of his tenure he assumed the head of Discovery Research (> 1200 FTEs) for Amgen. In this capacity, he charted the course and motivated a diverse senior team of scientific leaders from different disciplines as well as engaging and managing a diverse stakeholder network. At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders, and neuroscience.
Dr. Bruno Montanari is Member of the Supervisory Board of arGEN X BV. He is a Director at Omnes Capital's Life Sciences Venture Capital team, which he joined in January 2010. He began his career in 1999 in London as an Investment Banker in the Healthcare Groups of Deutsche Bank and Merrill Lynch, later joining the venture capital community first with CDP Capital and then Atlas Venture, responsible for several European portfolio companies in the biotech and medtech areas as board member or observer.
Dr. Harrold van Berlingen is Member of the Supervisory Board of arGEN X BV. He is the Managing Director and Founder of Thuja Capital. He headed the life sciences effort of AlpInvest Partners managing a portfolio of over 30 companies, prior to founding Thuja Capital in 2006. Dr. van Barlingen joined AlpInvest Partners in 2001, from the Boston Consulting Group (BCG), where he worked as a consultant in management and strategy. Before BCG, he was acting head of the continental activities of the Lewin Group (a Quintiles subsidiary), an internationally active firm specialized in the field of health economics.
The Wall